Rasagiline irreversibly acylates the flavin site of MAO-B, giving approximately 90% inhibition at 1 mg/day within 1-2 weeks. Although its plasma half-life is approximately 3 h, functional recovery depends on MAO-B resynthesis (approximately 40 days), so a single 1 mg dose can keep tyramine thresholds lower for several days. Selectivity diminishes above 2 mg/day, raising dietary and pressor risk comparable to classical non-selective MAOIs. Case surveys and pharmacovigilance reviews document serotonin-syndrome clusters when rasagiline is combined with SSRIs or MDMA-like agents—even at therapeutic doses. Bluelight users typically employ 0.5-1 mg to amplify phenethylamine or stimulant effects, reporting brighter mood, clearer focus, and longer stimulant plateau, but also warn that >2 mg 'feels wired' and makes tyramine flushes more likely.
Rasagiline molecular structure diagram from the DrugsPRO substance library.
Also known as: Azilect, Tvp-1012, Agn-1135
Classification
Chemical: Aminoindane
Chemical: Medicine
Tag: MAO-B-inhibitor
Tag: Not psychoactive
Tag: Pharmaceutical
Tag: Propargylamine
Effects
Reduced Fatigue
Slight Appetite Suppression
Occasional Insomnia
Subtle Mental Alertness
Enhanced Motivation
Mild Euphoria
Vivid Dreams
Routes of Administration
Oral (Tablet; Sublingually Dissolved)
Dosage
Threshold: 0.25 mg
Light: 0.25-0.5 mg
Common: 0.5-1 mg
Strong: 1-2 mg
Heavy: 2 mg
Duration
Onset: 0.5-1 h
Peak: 1-2 h
Offset: 12-24 h
After Effects: 12 h
Oral (Powder / Capsule)
Dosage
Threshold: 0.25 mg
Light: 0.25-0.5 mg
Common: 0.5-1 mg
Strong: 1-2 mg
Heavy: 2 mg
Duration
Onset: 0.5-1 h
Peak: 1-2 h
Offset: 12-24 h
After Effects: 12 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
